410 results on '"Daubert, Jean-Claude"'
Search Results
2. Cryoballoon ablation of atrial fibrillation in patients with atypical right pulmonary vein anatomy
3. Heart failure with preserved ejection fraction: A clustering approach to a heterogenous syndrome
4. The challenging right inferior pulmonary vein: A systematic approach for successful cryoballoon ablation
5. Localization of Residual Conduction Gaps After Wide Antral Circumferential Ablation of Pulmonary Veins
6. A novel method for localization and ablation of conduction gaps after wide antral circumferential ablation of pulmonary veins
7. Left Ventricular Architecture, Long-Term Reverse Remodeling, and Clinical Outcome in Mild Heart Failure With Cardiac Resynchronization: Results From the REVERSE Trial
8. Localization of gaps during redo ablations of paroxysmal atrial fibrillation: Preferential patterns depending on the choice of cryoballoon ablation or radiofrequency ablation for the initial procedure
9. Long‐term outcomes in heart failure with preserved ejection fraction: Predictors of cardiac and non‐cardiac mortality
10. Pacemaker replacement in nonagenarians: Procedural safety and long-term follow-up
11. First experience of intraoperative echocardiography-guided optimization of cardiac resynchronization therapy delivery
12. L’avenir des dispositifs électriques implantables à visée cardiaque
13. Baseline characteristics of patients with heart failure and preserved ejection fraction included in the Karolinska Rennes (KaRen) study
14. The effect of cardiac resynchronization without a defibrillator on morbidity and mortality: an individual-patient-data meta-analysis of COMPANION and CARE-HF
15. Very late effects of dual chamber pacing therapy for obstructive hypertrophic cardiomyopathy
16. Causes-of-death analysis of patients with cardiac resynchronization therapy: an analysis of the CeRtiTuDe cohort study
17. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy:Developed by the Task Force on cardiac pacing and cardiac resynchronization therapy of the European Society of Cardiology (ESC) With the special contribution of the European Heart Rhythm Association (EHRA)
18. Resynchronisation électrique du cœur : passé, présent et futur
19. Guidelines issued by the French Society of Cardiology concerning the competence, performance and environment required in the practice of diagnostic and interventional cardiac electrophysiology
20. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial
21. Is cardiac resynchronization therapy an option in heart failure patients with preserved ejection fraction? Justification for the ongoing KaRen project
22. 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
23. Predictors of long‐term outcome in heart failure with preserved ejection fraction: a follow‐up from the KaRen study
24. Cardiac resynchronization therapy in heart failure patients with less severe left ventricular dysfunction
25. Incidence of atrial fibrillation during very long-term follow-up after radiofrequency ablation of typical atrial flutter
26. Sustained positive impact of a coronary rehabilitation programme on adherence to dietary recommendations
27. Selection of patients responding to cardiac resynchronisation therapy: Implications for echocardiography
28. Redefining the Classifications of Response to Cardiac Resynchronization Therapy: Results From the REVERSE Study
29. A Randomized Comparison of Triple-Site Versus Dual-Site Ventricular Stimulation in Patients With Congestive Heart Failure
30. Right ventricular pump function after cardiac resynchronization therapy: A strain imaging study
31. Association between cardiovascular vs. non-cardiovascular co-morbidities and outcomes in heart failure with preserved ejection fraction
32. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry†
33. 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: The Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA)
34. Will mechanical dyssynchrony one day impact our management of chronic heart failure patients?
35. Eligibility of patients with heart failure with preserved ejection fraction for sacubitril/valsartan according to the PARAGON‐HF trial.
36. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management: A registered branch of the European Society of Cardiology (ESC), and the Heart Rhythm Society; and in collaboration with the Heart Failure Society of America (HFSA), the American Society of Echocardiography (ASE), the American Heart Association (AHA), the European Association of Echocardiography (EAE) of the ESC and the Heart Failure Association of the ESC (HFA).: Endorsed by the governing bodies of AHA, ASE, EAE, HFSA, HFA, EHRA, and HRS
37. Heart failure with a preserved ejection fraction additive value of an exercise stress echocardiography
38. Long-term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) trial
39. A randomized trial of long-term remote monitoring of pacemaker recipients (The COMPAS trial)
40. Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study
41. Clinical evaluation of cardiovascular devices: principles, problems, and proposals for European regulatory reform: Report of a policy conference of the European Society of Cardiology†
42. Cost-effectiveness of cardiac resynchronization therapy in patients with asymptomatic to mild heart failure: insights from the European cohort of the REVERSE (Resynchronization Reverses remodeling in Systolic Left Ventricular Dysfunction)
43. Commentary: Use of registries to investigate the past and develop the future
44. Optimal Lead Placement Strategy for Cardiac Resynchronization Therapy in Non–Left Bundle Branch Block Patients
45. Myeloperoxidase and related biomarkers are suggestive footprints of endothelial microvascular inflammation in HFpEF patients
46. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resynchronization therapyDeveloped with the special contribution of the Heart Failure Association and the European Heart Rhythm Association
47. 2010 Focused Update of ESC Guidelines on device therapy in heart failure: An update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association
48. EHRA Expert Consensus Statement on the management of cardiovascular implantable electronic devices in patients nearing end of life or requesting withdrawal of therapy
49. Resumption of sinus rhythm in patients with heart failure and permanent atrial fibrillation undergoing cardiac resynchronization therapy: a longitudinal observational study
50. Frightening ST-segment elevation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.